Carbonic Anhydrase
Carbonate dehydratase
Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.
The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.
Carbonic Anhydrase Isoform Specific Products
-
Carbonic Anhydrase
(193)
View all products
-
CA
(7)
View all products
-
CA I
(67)
View all products
-
CA Ⅱ
(119)
View all products
-
CA IX
(106)
View all products
-
CA XII
(64)
View all products
-
CA VII
(1)
View all products
-
CA VI
(2)
View all products
-
CA VA
(2)
View all products
-
CA VB
(2)
View all products
-
CA XIII
(2)
View all products
-
CA XIV
(2)
View all products
All Product Categories
-
Carbonic Anhydrase Inhibitors
(341)
View all products
-
Carbonic Anhydrase Activators
(6)
View all products
-
Carbonic Anhydrase Modulators
(4)
View all products
-
Carbonic Anhydrase Degrader
(1)
View all products
-
Carbonic Anhydrase Ligands
(3)
View all products
-
Carbonic Anhydrase Proteins
(33)
View all products
-
Carbonic Anhydrase 1 (CA1) Proteins
(1)
View all products
-
Carbonic Anhydrase 2 (CA-II) Proteins
(3)
View all products
-
Carbonic Anhydrase 4 (CA IV) Proteins
(3)
View all products
-
Carbonic Anhydrase 12 (CA-XII) Proteins
(1)
View all products
-
Carbonic Anhydrase Related Products (381)
Related Products (381)
-
Recombinant Proteins (33)
-
Carbonic Anhydrase Isoform Comparison
-
DSR-71167
0 ImagesCat. No.: HY-120321CAS No.: 1355687-91-0DSR-71167 is an orally active mineralocorticoid receptor (MR) antagonist with an IC50 of 0.26 μM. DSR-71167 exhibits weak carbonic anhydrase (CA) inhibitory activity with an IC50 of 19 μM. DSR-71167 can dose-dependently increase urinary sodium excretion in rat models and has a very low risk of hyperkalemia in potassium-loading rat models. DSR-71167 lowers systolic blood pressure in hypertensive rat models. DSR-71167 can be used for research on hypertension and heart failure.
-
CAI/II-IN-13
0 ImagesCat. No.: HY-178922CAI/II-IN-13 (Compound 5f) is a CAI/II inhibitor, with IC50 values of 309.16 nM for hCA I and 267.27 nM for hCA II. CAI/II-IN-13 exhibits potent and selective antiproliferative activity against A549 lung cancer cells (IC50 = 0.58 μM). CAI/II-IN-13 can be used for the study of lung cancer.
-
hCA I-IN-2
0 ImagesCat. No.: HY-147986CAS No.: 2417232-12-1hCA I-IN-2 (Compound 6d) is a selective human carbonic anhydrase I (hCA I) inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively.
-
BChE/hCA II-IN-1
0 ImagesCat. No.: HY-178017BChE/hCA II-IN-1 (Compound 20) is a dual-functional inhibitor of Butyrylcholinesterase (BChE) and human carbonic anhydrase II (hCA II) with IC50s of 76.50 and 10.69 μM for BChE and hCA II, respectively. BChE/hCA II-IN-1 can be used for neurodegenerative diseases like Alzheimer's and glaucoma research.
-
Topiramate lithium
0 ImagesCat. No.: HY-B0122ACAS No.: 488127-53-3Synonyms: McN 4853 lithium; RWJ 17021 lithiumTopiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
-
WES-1
0 ImagesCat. No.: HY-155522CAS No.: 2748673-86-9WES-1 (Compound 8g) is an inhibitor of carbonic anhydrase IX (Ki: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines.
-
hCAIX/XII-IN-5
0 ImagesCat. No.: HY-150695CAS No.: 2421127-99-1hCAIX/XII-IN-5 (Coumarin 9a) a carbonic anhydrase (CA) inhibitor, and exhibits excellent hCA IX/XII selectivity (Ki=93.9 and 85.7 nM, respectively) over hCA I and hCA II. hCAIX/XII-IN-5 shows anti-proliferative activities to cancer cells. hCAIX/XII-IN-5 can delay cell cycle and induce apoptosis.
-
Carbonic anhydrase inhibitor 26
0 ImagesCat. No.: HY-168124Carbonic anhydrase inhibitor 26 (compund 6T) is a carbonic anhydrase II inhibitor with IC50 of 9.10 ± 0.26 μM.
-
CAXII-IN-3
0 ImagesCat. No.: HY-178030CAXII-IN-3 is an effective carbonic anhydrase (CA XII) inhibitor with a Ki of 53 nM. CAXII-IN-3 exhibits selective inhibition against multiple human CA subtypes with Kis of 5.3 μM, 75 nM, 1.9 μM, > 10 μM against CA I, CA II, CA IV and CA IX. CAXII-IN-3 mainly inhibits CA II and XII, and reduces aqueous humor production. CAXII-IN-3 exhibits β3-AR agonistic activity, can dilate retinal blood vessels, and improve optic nerve perfusion. CAXII-IN-3 can be used in the research of ocular disorders such as glaucoma.
-
COX-2-IN-67
0 ImagesCat. No.: HY-184292COX-2-IN-67 is an orally active, blood-brain barrier permeable multi-target inhibitor that potently targets COX-2 (IC50=0.07 μM), hCA IX (Ki=62.7 nM) and hBuChE (IC50=0.47 μM). COX-2-IN-67 alleviates oxidative stress and liver stress, improves glucose homeostasis and insulin sensitivity, and optimizes lipid profiles. Meanwhile, COX-2-IN-67 effectively reduces the levels of neuroinflammatory markers and improves hippocampus-dependent cognitive function in a high-fat diet-induced rat model. COX-2-IN-67 can be used for the research of metabolic dysfunction-associated mild cognitive impairment.
-
Carbonic anhydrase inhibitor 17
0 ImagesCat. No.: HY-161174CAS No.: 3033849-05-4Carbonic anhydrase inhibitor 17 (compound 7c) ,pyridazine-tethered sulfonamide, is a carbonic anhydrase II inhibitor with IC50 of 0.63 nM.
-
CDK2-IN-12
0 ImagesCat. No.: HY-150573CAS No.: 2410402-88-7CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity.
-
CAII-IN-12
0 ImagesCat. No.: HY-180056CAII-IN-12 (compound 6c) is a potent and selective carbonic anhydrase (CA) II and VII inhibitor (hCA II Ki = 47.8 nM, hCA VII Ki = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (Ki = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research.
-
Zonisamide-15N,d4
0 ImagesCat. No.: HY-B0124S3CAS No.: 2308764-57-8Zonisamide-15N,d4 is the 15N- and deuterium labeled Zonisamide (HY-B0124). Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
-
COX-2/CA II-2
0 ImagesCat. No.: HY-184938COX-2/CA II-2 is an orally active dual selective inhibitor targeting COX-2 and hCA II. COX-2/CA II-2 inhibits COX-2 with an IC50 value of 0.05 μM (SI = 12.02 vs COX-1) and hCA II with a Ki value of 62.6 nM (SI = 704.2 vs hCA I). COX-2/CA II-2 demonstrates significant analgesic and anti-inflammatory effects with rapid onset and sustained duration in animal models, shows improved gastric safety with reduced ulcerogenic liability, and exhibits a gradual intraocular pressure (IOP)-lowering effect without statistical significance relative to the sham-treated eye in rabbit glaucoma models. COX-2/CA II-2 can be used for anti-inflammatory, analgesic and antiglaucoma research.
-
hCA/VEGFR-2-IN-3
0 ImagesCat. No.: HY-155760CAS No.: 2971782-73-5hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC50=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells.
